Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Antibe Therapeutics (TSXV:ATE,OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has received approval from Health Canada to initiate the second part of its Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346.

As quoted in the press release:

Antibe’s CEO, Dan Legault, commented, “This is an exciting time for Antibe as a significant number of patients will be receiving ATB-346 for the first time to assess efficacy in a controlled setting. A positive outcome in this Phase 2B study will validate the effectiveness of ATB-346 in reducing pain, and will be a breakthrough for patients and physicians. Furthermore, it will unlock significant value for Antibe as we advance global partnering discussions and deepen our understanding of the ideal development path for ATB-346 and our other pipeline drug candidates.”

The study will be conducted by Veristat, in approximately 35 clinical sites across Canada and is expected to commence enrollment shortly. Antibe will update the timing for the trial completion as Veristat informs us of enrollment progress during the coming months.

Click here to read the full press release.